5 Stocks to Watch: Week of 10/19/2026

Lucky you. We’ve got a truly excellent list of stocks to watch in the coming week, including:

• Bioventus (BVS): Strategic review underway with 45% upside target
• Nvidia (NVDA): Ten top-1% analysts see up to 70% upside
• Arlo Technologies (ARLO): Subscription pivot driving up to 60% upside
• Tactile Systems Technology (TCMD): Recent dip opens 75% upside window
• Belden (BDC): Ruckus deal unlocks cross-selling and big upside targets
• Precigen (PGEN): FDA-approved launch tracking ahead, 140% upside target

A note from our sponsors...

Where Investors Can Still Find 10X Opportunities

Some of the biggest investment gains come from small, overlooked markets. Legendary international speculator Doug Casey has spent more than 50 years looking for exactly these situations. In a new free report, he reveals 3 contrarian stocks he likes right now – and why he believes some neglected corners of the market could still offer 10X, even 100X, upside.

Click here to get your free copy.

1- Bioventus (NASDAQ: BVS)

This medical device company is currently exploring strategic alternatives to maximize shareholder value, presenting a compelling catalyst as it demonstrated solid Q2 execution with revenue growth and continued positive momentum heading into the second half of 2026.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $13.82 — get current quote

Max 1-year forecast: $19.00

Why we're watching:

• BVS has limited, but overall bullish, coverage among the analysts we track, with 2 Strong Buy and 1 Buy recommendations. See all recommendations here
• For example, Canaccord Genuity researcher Caitlin Cronin (a top 18% rated analyst) recently maintained her Strong Buy recommendation with a price target 41% above current levels. 
• Q2 earnings demonstrated execution strength: EPS of $0.22 beat estimates by 4.8% with 5% year-over-year growth, while revenue of $153.21M declined 1.16% against estimates but grew 3.73% YoY.
• Despite this fact, the stock has dipped recently … leading to our Editor-in-Chief alerting BVS as his Stock of the Week, where he called it a “juice buy the dip opportunity.” Find out why.
• Industry ranking context: BVS is currently the #1 highest-rated stock in the Medical Device industry, which has an Industry Rating of C.
• Zen Ratings highlights: BVS earns an overall A rating, equal to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
• Component Grades: BVS excels with an A for Financials, reflecting strong operational efficiency and disciplined cash management, while maintaining solid Bs for Growth, Safety, Momentum, and Value, positioning it well as the strategic review unfolds. See all 7 Component Grades here

A note from our sponsors...

Hoping to Retire Soon?

There's a 73-minute "trading window" that is commonly exploited by retirees and those hoping to retire sooner. It works best if you can make this trade at a very specific time of day. 

Click here to know when you should make this morning trade.

Nvidia (NASDAQ: NVDA)

With dominant positioning in AI and data center infrastructure, the tech titan continues to extend its growth runway through technological innovation and expanding partnerships across gaming, automotive, and enterprise computing segments.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $216.71 — get current quote

Max 1-year forecast: $515.00

Why we're watching: 

• NVDA has exceptionally broad, bullish coverage among the analysts we track, with 20 Strong Buy and 10 Buy recommendations. See all recommendations here
• Cantor Fitzgerald researcher C.J. Muse (a top 2% rated analyst) recently reiterated his Strong Buy recommendation with a price target over 55% above current levels. 
• Even better, Rosenblatt researcher Kevin Cassidy (a top 1% rated analyst) recently maintained his Strong Buy recommendation with a price target roughly 75% above current levels.
• Eight additional analysts ranked in the top 1% of our system for stock-picking prowess maintain bullish outlooks on the semiconductor leader's AI growth trajectory.
• Industry ranking context: NVDA is currently the #5 highest-rated stock in the Semiconductor industry, which has an Industry Rating of A.
• Zen Ratings highlights: NVDA earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks with this rating have historically delivered nearly 30% annual returns, consistently outperforming the broader market.
• Component Grades: NVDA excels with an A for Financials, reflecting its fortress balance sheet and market leadership, while maintaining strong Bs for Sentiment and Momentum, a powerful combination for sustained appreciation in the AI era. See all 7 Component Grades here

3- Precigen (NASDAQ: PGEN)

Precigen is an American gene and cellular therapy company that has recently gained FDA approval for the sole approved treatment for adult recurrent respiratory papillomatosis. With commercial launch tracking ahead of recent rare oncology releases and strong Q2 sales momentum, the company is positioned at an inflection point as it transitions from development to commercialization.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $7.23 — get current quote

Max 1-year forecast: $18.00

Why we're watching:

• PGEN has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy and 2 Buy recommendations. See all recommendations here
• For example, B. Riley Securities researcher Yuan Zhi (a top 8% rated analyst) initiated coverage with a Strong Buy recommendation and a price target representing over 60% upside potential from current levels, highlighting that Papzimeos' commercial launch is tracking ahead of recent releases in rare oncology.
• Even more exciting, HC Wainwright & Co. researcher Swayampakula Ramakanth (a top 3% rated analyst) maintained his Buy recommendation with a price target 145% above current levels. 
• Our Editor-in-Chief highlighted PGEN as one of his Trade of the Week picks in his most recent no-paywall webinar … To gain access to his next picks, sign up at wallstreetzen.com/live. 
• Industry ranking context: PGEN is currently the #2 highest-rated stock in the Biotech industry, which has an Industry Rating of F.
• Zen Ratings highlights: PGEN earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all 4,600+ stocks tracked based on a rigorous 115-factor fundamental review.
• Component Grades: PGEN excels with strong As for Growth, Momentum, Sentiment, and Artificial Intelligence, reflecting the company's promising pipeline and accelerating commercial traction in the gene therapy space. See all 7 Component Grades here

4- Tactile Systems Technology (NASDAQ: TCMD)

This medical technology firm has a lot going for it RN: accelerating earnings growth, strong operating leverage, and an attractive entry point following recent price dips … On top of that, the company is well-positioned to continue its trajectory of revenue expansion and margin improvement.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $22.41 — get current quote

Max 1-year forecast: $36.00

Why we're watching:

• TCMD has limited, but overall bullish, coverage among the analysts we track, with 2 Strong Buy recommendations. See all recommendations here
• For example, B. Riley Securities researcher Kyle Bauser (a top 21% rated analyst) upgraded to Strong Buy with a price target that suggests the stock could see roughly 60% upside in the coming year. 
• Even better, BTIG researcher Ryan Zimmerman (a top 20% rated analyst) recently maintained his Strong Buy rating with a price target that suggests the stock could see nearly 57% upside in the coming year. 
• Industry ranking context: TCMD is currently the #4 highest-rated stock in the Medical Device industry, which has an Industry Rating of C.
• Zen Ratings highlights: TCMD earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all stocks tracked based on a rigorous 115-factor fundamental review.
• Component Grades: TCMD earns solid Bs for Value, Sentiment, Safety, and Financials, reflecting steady analyst confidence and a stable financial footing, while Cs for Growth, Momentum, and AI suggest the stock is more of a steady holding than a near-term breakout play. See all 7 Component Grades here

5- Arlo Technologies (NYSE: ARLO)

Arlo Technologies provides smart connected devices to monitor environments in real-time with Wi-Fi or cellular connections. Recent product innovations including the Essential Solar Security Camera and new AI-powered Secure 7 service are driving the company's evolution from hardware to higher-margin subscription revenue streams.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $12.11 — get current quote

Max 1-year forecast: $20.00

Why we're watching:

• ARLO has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy and 2 Buy recommendations. See all recommendations here
• The most bullish analyst is Piper Sandler researcher James Fish (a top 9% rated analyst), who recently maintained his Strong Buy with a price target roughly 50% above current levels. 
• Technically Oppenheimer researcher Martin Yang (a top 4% rated analyst) is slightly less bullish, having just initiated coverage with a Buy recommendation … but their price target exceeds Fish’s, with over 69% upside on the table.
• Industry ranking context: ARLO is currently the #2 highest-rated stock in the Building Product & Equipment industry, which has an Industry Rating of B.
• Zen Ratings highlights: ARLO earns an overall A rating, equal to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, decisively beating the broader market.
• Component Grades: ARLO maintains solid Bs across Sentiment, Growth, and Value, reflecting a company scaling its recurring revenue base with analyst support behind the shift and a valuation that hasn’t run ahead of it. See all 7 Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.